BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 25216573)

  • 1. Delineation of small mobile tumours with FDG-PET/CT in comparison to pathology in breast cancer patients.
    Hapdey S; Edet-Sanson A; Gouel P; Martin B; Modzelewski R; Baron M; Berghian A; Forestier-Lebreton F; Georgescu D; Picquenot JM; Gardin I; Dubray B; Vera P
    Radiother Oncol; 2014 Sep; 112(3):407-12. PubMed ID: 25216573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of prone versus supine 18F-FDG-PET of locally advanced breast cancer: Phantom and preliminary clinical studies.
    Williams JM; Rani SD; Li X; Arlinghaus LR; Lee TC; MacDonald LR; Partridge SC; Kang H; Whisenant JG; Abramson RG; Linden HM; Kinahan PE; Yankeelov TE
    Med Phys; 2015 Jul; 42(7):3801-13. PubMed ID: 26133582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serial assessment of FDG-PET FDG uptake and functional volume during radiotherapy (RT) in patients with non-small cell lung cancer (NSCLC).
    Edet-Sanson A; Dubray B; Doyeux K; Back A; Hapdey S; Modzelewski R; Bohn P; Gardin I; Vera P
    Radiother Oncol; 2012 Feb; 102(2):251-7. PubMed ID: 21885145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preoperative 18F-FDG PET/CT predicts disease-free survival in patients with primary invasive ductal breast cancer.
    Jo JE; Kim JY; Lee SH; Kim S; Kang T
    Acta Radiol; 2015 Dec; 56(12):1463-70. PubMed ID: 25406431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intra-tumour 18F-FDG uptake heterogeneity decreases the reliability on target volume definition with positron emission tomography/computed tomography imaging.
    Dong X; Wu P; Sun X; Li W; Wan H; Yu J; Xing L
    J Med Imaging Radiat Oncol; 2015 Jun; 59(3):338-45. PubMed ID: 25708154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Variations in (18)F-FDG uptake in breast cancer depending on PET/CT acquisition position.
    Lee JH; Jeon TJ; Ahn SG; Jeong J; Seok JW; Ryu YH
    Clin Radiol; 2016 Jan; 71(1):86-91. PubMed ID: 26646369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of ¹⁸F-FDG PET/MRI, ¹⁸F-FDG PET/CT, MRI, and CT in whole-body staging of recurrent breast cancer.
    Sawicki LM; Grueneisen J; Schaarschmidt BM; Buchbender C; Nagarajah J; Umutlu L; Antoch G; Kinner S
    Eur J Radiol; 2016 Feb; 85(2):459-65. PubMed ID: 26781152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumour delineation in oesophageal cancer - A prospective study of delineation in PET and CT with and without endoscopically placed clip markers.
    Thomas L; Lapa C; Bundschuh RA; Polat B; Sonke JJ; Guckenberger M
    Radiother Oncol; 2015 Aug; 116(2):269-75. PubMed ID: 26364886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initial experience of integrated PET/MR mammography in patients with invasive ductal carcinoma.
    Kong EJ; Chun KA; Bom HS; Lee J; Lee SJ; Cho IH
    Hell J Nucl Med; 2014; 17(3):171-6. PubMed ID: 25397622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor metabolism and perfusion ratio assessed by 18F-FDG PET/CT and DCE-MRI in breast cancer patients: Correlation with tumor subtype and histologic prognostic factors.
    An YS; Kang DK; Jung YS; Han S; Kim TH
    Eur J Radiol; 2015 Jul; 84(7):1365-70. PubMed ID: 25886700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of five segmentation tools for 18F-fluoro-deoxy-glucose-positron emission tomography-based target volume definition in head and neck cancer.
    Schinagl DA; Vogel WV; Hoffmann AL; van Dalen JA; Oyen WJ; Kaanders JH
    Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1282-9. PubMed ID: 17967318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of FDG-PET/CT at the postoperative surveillance in the breast cancer patients.
    Jung NY; Yoo IR; Kang BJ; Kim SH; Chae BJ; Seo YY
    Breast Cancer; 2016 Jan; 23(1):141-148. PubMed ID: 24872087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FDG-PET/CT detection of very early breast cancer in women with breast microcalcification lesions found in mammography screening.
    Peng NJ; Chou CP; Pan HB; Chang TH; Hu C; Chiu YL; Fu TY; Chang HT
    J Med Imaging Radiat Oncol; 2015 Aug; 59(4):445-452. PubMed ID: 25872026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual time point 2-deoxy-2-[18F]fluoro-D-glucose PET/CT: nodal staging in locally advanced breast cancer.
    García Vicente AM; Soriano Castrejón A; Cruz Mora MÁ; Ortega Ruiperez C; Espinosa Aunión R; León Martín A; González Ageitos A; Van Gómez López O
    Rev Esp Med Nucl Imagen Mol; 2014; 33(1):1-5. PubMed ID: 23707190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual time point FDG-PET/CT imaging... Potential tool for diagnosis of breast cancer.
    Zytoon AA; Murakami K; El-Kholy MR; El-Shorbagy E
    Clin Radiol; 2008 Nov; 63(11):1213-27. PubMed ID: 18929039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 18F-FDG semi-quantitative parameters and biological prognostic factors in locally advanced breast cancer.
    García Vicente AM; Soriano Castrejón A; Relea Calatayud F; Muñoz Madero V; Molina Garrido MJ; León Martín AA; Cordero García JM; Pilkington Woll JP; Chacón López-Muñiz I; Palomar Muñoz A
    Rev Esp Med Nucl Imagen Mol; 2012; 31(6):308-14. PubMed ID: 23084013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of FDG-PET/CT and CT for delineation of lumpectomy cavity for partial breast irradiation.
    Ford EC; Lavely WC; Frassica DA; Myers LT; Asrari F; Wahl RL; Zellars RC
    Int J Radiat Oncol Biol Phys; 2008 Jun; 71(2):595-602. PubMed ID: 18394814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
    Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS
    PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Additional Prone 18F-FDG PET/CT Acquisition to Improve the Visualization of the Primary Tumor and Regional Lymph Node Metastases in Stage II/III Breast Cancer.
    Teixeira SC; Koolen BB; Vogel WV; Wesseling J; Stokkel MP; Vrancken Peeters MJ; van der Noort V; Rutgers EJ; Valdés Olmos RA
    Clin Nucl Med; 2016 Apr; 41(4):e181-6. PubMed ID: 26704731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Whole-Body Metabolic Tumor Volume, as Determined by (18)F-FDG PET/CT, as a Prognostic Factor of Outcome for Patients With Breast Cancer Who Have Distant Metastasis.
    Son SH; Lee SW; Jeong SY; Song BI; Chae YS; Ahn BC; Lee J
    AJR Am J Roentgenol; 2015 Oct; 205(4):878-85. PubMed ID: 26204115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.